JERUSALEM, Ocobert 23 (Reuters) - Israel's Teva Pharmaceutical Industries said today it received final U.S. Food & Drug Administration approval to manufacture and market Doxazosin Mesylate 1, 2, 4 and 8 mg tablets. Doxazosin is the generic version of Pfizer Inc's (NYSE:PFE - news) cardiovascular/benign prostate hyperplasma drug, Cardura.

Combined branded sales of Cardura were $320 million in 1999, Teva said in a statement.

Teva said it received the final approval upon the expiration of the patent of Cardura, adding it would begin to ship its version in December 2000. Other drug companies also received FDA approvals, Teva said.

Teva's shares closed fractionally lower at $64-3/8 in Friday's Nasdaq trade.